Donor-derived cell-free DNA levels predict 3-year outcomes in kidney transplant recipients with stable function
Donor-derived cell-free DNA (dd-cfDNA) is a promising noninvasive biomarker for detecting acute rejection in kidney transplant recipients, but its prognostic value in patients with stable graft function remains unclear. This study evaluated the association between dd-cfDNA levels and long-term clinical outcomes. We retrospectively analyzed 267 kidney transplant recipients with stable renal function between January 2020 and July 2023, stratified by plasma dd-cfDNA levels into three groups: A (<1%, n = 205), B (1–<2%, n = 34), and C (≥2%, n = 28). Each patient contributed a single index dd-cfDNA measurement obtained during routine outpatient follow-up, which defined baseline; the interval from transplantation to the index measurement did not differ among groups (p = 0.124). Clinical outcomes included changes in serum creatinine, incidence of adverse events, graft loss, patient mortality, and biopsy findings over three years. Creatinine levels remained stable in Group A but increased significantly in Groups B and C from baseline to year 3 (1.38 to 1.96 mg/dL, p < 0.0001; and 1.36 to 1.84 mg/dL, p = 0.0019, respectively). Adverse events were significantly more frequent in Groups B (41.2%) and C (42.9%) compared with Group A (9.8%, p < 0.001). Graft loss rates were 0.98%, 11.76%, and 7.14% in Groups A, B, and C, respectively (p = 0.002), and mortality showed a significant increasing trend across groups (p = 0.023). Elevated dd-cfDNA levels are associated with adverse long-term outcomes in kidney transplant recipients with stable graft function, suggesting that dd-cfDNA may serve as a valuable tool for early risk stratification and long-term monitoring in transplant care.
Authors
- Jinsong Chen (ORCID: https://orcid.org/0000-0002-6049-9259)
- Tingya Jiang (ORCID: https://orcid.org/0000-0002-2418-206X)
- Xuefeng Ni (ORCID: https://orcid.org/0009-0007-5782-1570)
- Dongrui Cheng (ORCID: https://orcid.org/0000-0003-4380-9603)
- Cuello Garcia Haider (ORCID: https://orcid.org/0009-0009-6671-7067)
- Li Xue (ORCID: https://orcid.org/0000-0002-8313-3671)
- Zhou Yang
- Xiaohui Xu
- Kenan Xie
Institutions
- Jiangsu University (CN)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Viva Biotech (China) (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Renal Failure
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1080/0886022x.2026.2751271
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00